Eisai announces the amalgamation of its Indian entities

April 15, 2015
Eisai Pharmaceuticals India Pvt. Ltd.

MUMBAI / VISAKHAPATNAM -- Eisai Pharmaceuticals India Pvt. Ltd (Managing Director: Dr. Sanjit Singh Lamba, “Eisai India”) announced today that Eisai Pharmatechnology and Manufacturing Pvt. Ltd. (Location: Visakhapatnam) and Eisai Pharmaceuticals India Pvt. Ltd. (Location: Mumbai), two subsidiaries of Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), have been amalgamated and the new entity shall be known as “Eisai Pharmaceuticals India Pvt. Ltd”. The amalgamation of the two subsidiaries was completed to leverage the capability of Eisai India’s state-of-the art integrated research and manufacturing operations with its specialized sales force to meet its business objectives in India. This also provides a more rationalized structure for better efficiency.

Dr. Sanjit Singh Lamba has been appointed as the Managing Director of Eisai Pharmaceuticals India Pvt. Ltd., the merged entity. Eisai Co., Ltd, a global R&D based pharmaceutical company. In line with its Human health care (hhc) mission, Eisai is committed to improving global access to medicines (ATM) over the medium- to long-term through partnership strategies that involve working with governments, international organizations, private entities and non-profit organizations.

Eisai, since launching its anti-Alzheimer's agent Aricept® (brand name in India: Aricep®) and proton pump inhibitor Pariet® (brand name in India: Parit™) in India in 2005, has been providing both drugs to patients at affordable prices. Halaven® (eribulinmesylate), a novel anticancer agent discovered and developed in-house by Eisai, is currently approved in more than 50 countries, including Japan, the United States and Europe. Halaven was approved in India in April 2013 for the treatment of locally advanced or metastatic breast cancer.

As part of the “HOPE TO HER” Patient Assistance Program (PAP), Eisai India introduced a tiered-pricing model for Halaven in which the cost burden to patients is differentiated according to income level, ranging from full payment by the patient to total reimbursement by Eisai.

As part of its commitment to this global initiative, Eisai has agreed to supply 2.2 billion diethylcarbamazine citrate (DEC) 100 mg tablets free of charge to the World Health Organization (WHO) under the Mass Drug Administration (MDA) program for eliminating lymphatic filariasis. Eisai has commenced the supply of DEC tablets from its Visakhapatnam Plant in Andhra Pradesh, India for a seven-year period from 2013 to 2020 across 26 targeted countries including India. In India, Eisai has started the distribution of DEC tablets with its supply of 60 million tablets to the State of Bihar followed by other states under the WHO agreement.

Eisai continues to promote its hhc philosophy and corporate mission, as well as contribute to patients and their family all over the world through discovering novel compounds and the stable supply of high quality products on a global basis.

Media Inquiries:
Eisai Pharmaceuticals India Pvt. Ltd.
Dr. Sanjit Singh Lamba
+91-891- 3047100
s-lamba@eisai.co.in



About Eisai Co., Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our Human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology. As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries. For more information about Eisai Co., Ltd., please visit www.eisai.com.

About Lymphatic Filariasis
Lymphatic Filariasis is a parasitic disease that is transmitted to humans by the bite of a mosquito. Once transmitted, it causes lymphatic dysfunction. While infection is usually acquired during childhood, symptoms gradually appear over several years, with the most serious manifestations of the disease occurring in adulthood. The most serious manifestation, known as elephantiasis, is a permanent physical disability in which a patient’s lower extremities swell to resemble those of an elephant. In addition to impacting a patient’s ability to perform everyday tasks, it historically has led to many patients falling victim to social persecution due to biases against the disease. The disease also causes patients and their families much emotional distress. Nowadays, lymphatic filariasis affects an estimated 120 million people in 81 countries worldwide, most of whom live in developing and emerging nations in Africa and South East Asia. The disease has been proven to have existed in Japan since the Heian Period (794-1184). However, Japan succeeded in eliminating lymphatic filariasis in the late 1970s as a result of initiatives carried out by the government in partnership with the public-private sector and became the first country in the world to demonstrate the successful achievement of lymphatic filariasis elimination using DEC.

Current Distribution Status of DEC Tablets for Endemic Countries

CII confers EHS excellence award -2014 on Eisai India, Vizag

The Confederation of Indian Industry CII (Southern Region) has conferred its prestigious Environment, Health, and Safety (EHS) Excellence 2014 Award to Eisai India, Visakhapatnam.

The aim of this award is to recognize, motivate, facilitate and acknowledge extraordinary contribution by organizations to adopt excellent practices in Environment Health & Safety.

About 130 companies from southern part of India participated in this very prestigious award and it a matter of great pride that Eisai India got 1st place in large scale industries under Chemicals/refineries/pharma/food sector.

Eisai India, Vizag was also awarded with ‘4 star rating trophy’ towards the commitment in Environment, Health and Safety Practices and policies for the year 2014. CII auditors made an on-site assessment of all the participating industries and evaluated their EHS systems & practices on about 150 parameters – based on the rating among all the contenders in large scale sector and also in Food/ pharma/chemical& refinery sector;Eisai India qualified for the said awards.

Achieving this CII-EHS Excellence awards and certificates of Merit by Eisai Indiafor consecutive 3 years just in a period of 5 years of its operations speaks a lot of its sound EHS systems, work culture, and practices in operations of this company.

On behalf of the company, awards were received by senior officials, i.e. Mr. Anand Galphade, and Mr. K. Srinivas Rao at a glittering function held at Hotel Park Sheraton in Chennai on 14th March 2015.

Eisai India "hhc" Activities



Distribution of Morbidity kits to the LF patients at Yarada Village, Visakhapatnam.





Interaction with the old age home patients at Goregaon, Mumbai

Eisai India’s DEC Tablets receive approval from WHO

Diethylcarbamazine (DEC )100mg tablets, from Eisai India, Vizag have been prequalified by World Health Organization (WHO) for the treatment of lymphatic filariasis, a neglected tropical disease (NTD).The approval is the first case worldwide in which a pharmaceutical company has received prequalification from WHO for a medicine used to treat an NTD.

These DEC tablets shall be supplied to various countries as part of WHO’s global program to eliminate Lymphatic filariasis, commonly known as elephantiasis, which is a threat to more than 1.3 billion people in 73 countries worldwide.

Eisai India, Vizag Wins Award of Excellence for its CSR Activities at UBM India Pharma Awards 2013

Eisai India, Vizag has bagged yet another award. This time it is winner of excellence award of UBM India for its hhc and CSR (Corporate Social Responsibility) activities. The award was given in Mumbai on 02nd December 2013.

UBM which has presence in over 30 countries in the world, has instituted such awards to give recognition to the Pharma companies who excel in CSR and other outstanding initiatives. The awards are also given for contribution in formulation process development and packaging.

The awards were witnessed by the leaders and experts from the Global Pharmaceutical Industry. With India now being the hub for high quality, low cost pharma solutions, India Pharma Awards give an opportunity to companies to engage with the movers and shakers in India's pharma machinery, technology, ingredients, outsourcing and Bio-Pharma industry.

The submissions for the said awards were evaluated and reviewed by a panel of Senior Executives from across the Pharmaceutical Industries. Eisai was declared as a winner on account of remarkable Corporate Social Responsibility activities which include Eisai’s commitment to supply 2.2 Billion tablets of DEC (Diethylcarbamazine Citrate) to WHO free of charge to support their mission of eradication of Lymphatic Filariasis by 2020 across the globe. In addition EISAI INDIA, VIZAG , as part of their hhc (human health care) philosophy, has been working extensively on patient socialization, increased access to medicine, spreading awareness in general public about Alzheimer’s disease and facilitating free checkups in their Memory Clinic in Vizag.